In this blog I will discuss our approach to scaling our AI technologies across multiple dimensions while controlling development costs, operational costs, and assuring stability. LLMs are a powerful new technology, but they also have large development, operational,...
This study characterized discontinuation and reinitiation of GLP-1 medications for a large population of patients with overweight or obesity who started a GLP-1 medication between 2018-2023. The study also identified factors associated with stopping and subsequently...
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%). Month-over-month anti-diabetic medication (ADM) prescribing increased in April and May 2024 then decreased slightly in June...
Today, Truveta kicks off Truveta Symposium, a unique event bringing together leaders from health systems, life sciences, and the government to collaborate on health research with real-world data, embracing generative AI to transform healthcare, and improving patient...
Truveta Research’s comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA Internal Medicine. Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications,...
Citation Wang X, Xu Y, Norman G, et al. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data. Diabetes. June 14, 2024. https://doi.org/10.2337/db24-1922-LB Recently, researchers published new insights in Diabetes exploring the...
In this post, I would like to discuss the way we addressed the following challenge: How to ensure that the AI technologies used in our platform have requisite accuracy and explainability while assuring fairness and avoidance of bias Healthcare and life science...
